BOSTON, Sept. 3,
2024 /PRNewswire/ -- Elevation Oncology, Inc.
(Nasdaq: ELEV), an innovative oncology company focused on the
discovery and development of selective cancer therapies to treat
patients across a range of solid tumors with significant unmet
medical needs, today announced that Joseph
J. Ferra, Chief Executive Officer of Elevation Oncology,
will participate in a fireside chat at the H.C. Wainwright
26th Annual Global Investment Conference on Tuesday, September 10, 2024, at 11:30 am ET.
A live webcast and replay of the event will be available on the
Events page of the Company's Investor Relations website at
https://investors.elevationoncology.com.
About Elevation Oncology, Inc.
Elevation Oncology is an innovative oncology company focused on
the discovery and development of selective cancer therapies to
treat patients across a range of solid tumors with significant
unmet medical needs. We are leveraging our antibody-drug conjugate
(ADC) expertise to advance a novel pipeline, initially targeting
two clinically validated targets in oncology, Claudin 18.2 and
HER3. Our lead candidate, EO-3021, is a potential best-in-class ADC
designed to target Claudin 18.2 and is currently being evaluated in
a Phase 1 trial (NCT05980416) in patients with advanced,
unresectable or metastatic solid tumors likely to express Claudin
18.2 including gastric, gastroesophageal junction, pancreatic or
esophageal cancers. Additionally, we expect to nominate a
development candidate for our second program, a HER3-targeting ADC
for the treatment of patients with solid tumors that overexpress
HER3, in 2024. For more information, visit
www.ElevationOncology.com.
Elevation Oncology Investor and Media Contact
Hannah Deresiewicz,
212-362-1200
EVP, Managing Director, Precision AQ
hannah.deresiewicz@precisionaq.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-to-present-at-the-hc-wainwright-26th-annual-global-investment-conference-302236283.html
SOURCE Elevation Oncology
